ALS Drugs: FDA Panel Weighed Less-Than-Ideal Data Against Amylyx’s Ability To Set Postapproval Price

 
• By Sue Sutter
  
Pill container with money
Some advisory committee members worried about giving Amylyx free rein to price its ALS drug based on suboptimal data. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers